After a Phase III failure less than two weeks ago, Marinus Pharmaceuticals needed a win for its lead compound ganaxolone. Unfortunately, a mid-stage study failed to meet its primary endpoint, but again, the company stayed positive.
Marinus announced June 28 that ganaxolone failed to meet its primary endpoint in a 59-patient Phase II study in Fragile...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)